Clinical outcomes related to evaluated drugs in KRAS-mutated nonsmall cell lung cancer patients
| Trial arm [ref.] | Patients | Previous lines | ORR % | DCR % | Median PFS months | Median OS months |
| MAPK pathway | ||||||
| Salirasib [24] | 33 | Any | 0 | 33.3 | ||
| Sorafenib [25] | 10 | ≥1 | 33.3 | 60 | 3 | |
| Sorafenib [26] | 59 | ≥1 | 8.5 | 50.8 | 2.3 | 5.3 |
| Sorafenib | 34 | ≥2 | 2.9 | 44.1 | 2.6 | 6.4 |
| versus placebo [27] | 34 | ≥2 | 0 | 7.6 | 1.7 (HR 0.46, 95% CI 0.25–0.82; p=0.007) | 5.1 (HR 0.76, 95% CI 0.45–1.26; p=0.279) |
| Sorafenib | 14 | ≥1 | 79 | |||
| versus erlotinib | 7 | ≥1 | 14 | |||
| versus erlotinib + bexarotene | 3 | ≥1 | 33 | |||
| versus vandetanib [28] | 14 | ≥1 | 0 | |||
| Selumetinib | 9 | ≥1 | 0 | 3.9 | ||
| versus selumetinib + erlotinib [29] | 30 | ≥1 | 6.7 | 4.5 | ||
| Selumetinib + docetaxel | 44 | ≥1 | 36.4 | 80 | 5.3 | 9.4 |
| versus docetaxel + placebo [30] | 43 | ≥1 | 0 | 46.5 | 2.1 (HR 0.58, 95% CI 0.42–0.79; p=0.014) | 5.2 (HR 0.8, 95% CI 0.56–1.14; p=0.21) |
| Trametinib | 86 | 1 | 11.6 | 90.7 | 3 | 8 |
| versus docetaxel [31] | 43 | 1 | 11.6 | 74.4 | 2.8 (HR 1.23, 95% CI 0.81–1.87; p=0.316) | Unreached (HR 0.97, 95% CI 0.52–1.83; p=0.934) |
| Trametinib + docetaxel [32] | 22 | ≥1 | 13.6 | 61 | ||
| Trametinib + pemetrexed [33] | 20 | ≥1 | 75 | 65 | ||
| mTOR inhibitors | ||||||
| Ridaforolimus [34] | 79 | ≥1 | 35.4 | |||
| Ridaforolimus | 14 | ≥1 sd after 8 weeks ridaforolimus | 4 | 18 | ||
| versus placebo [34] | 14 | ≥1 sd after 8 weeks ridaforolimus | 2 (HR 0.36, p=0.013) | 5 (HR 0.46, p=0.09) | ||
| Hsp90 inhibitor | ||||||
| Ganetespib [35] | 17 | ≥1 | 0 | 35 | 1.9 | 11.0 |
Data are presented as n, unless otherwise stated. ORR: objective response rate; DCR: disease control rate; PFS: progression-free survival; OS: overall survival; MAPK: mitogen-activated protein kinase; mTOR: mammalian target of rapamycin; Hsp90: heat shock protein 90; HR: hazard ratio.